Search Within

Martin Henner Voss

  1. "2019"
Formats
  1. Journal Article (11)
  2. Meeting Abstract (11)
  3. Review (2)
  4. Editorial (1)
  5. Guidelines (1)
  6. Research Letter (1)
Groups
  1. Department of Medicine (27)
  2. Genitourinary Oncology Service (27)
  3. Solid Tumor Oncology Division (27)
  4. Weinberg Fellows (18)
  5. Human Oncology and Pathogenesis Program (12)
  6. Surgery (12)

More Groups

People
  1. Robert Motzer (19)
  2. Abraham Hakimi (12)
  3. Chung-Han Lee (9)
  4. Darren Feldman (9)
  5. Maria Carlo (9)
  6. Almedina Djesevic (8)

More People

Years
  1. 2019 (27)
Publications
  1. Journal of Clinical Oncology (9)
  2. Clinical Cancer Research (3)
  3. Cancer Discovery (2)
  4. Clinical Genitourinary Cancer (2)
  5. Annals of Oncology (1)
  6. Annals of Translational Medicine (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (10)
  2. American Association for Cancer Research (6)
  3. Elsevier Inc. (4)
  4. Nature Publishing Group (2)
  5. AME Publishing Company (1)
  6. Biomed Central Ltd (1)

More Publishers

Results (27)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)
    Guidelines

    Rini, B. I.; Battle, D.; Figlin, R. A.; George, D. J.; Hammers, H.; Hutson, T.; Jonasch, E.; Joseph, R. W.; McDermott, D. F.; Motzer, R. J.; more...
    Journal for ImmunoTherapy of Cancer (2019)

    Fulltext@MSK | Save
  • Comprehensive genomic analysis of metastatic non–clear-cell renal cell carcinoma to identify therapeutic targets
    Journal Article

    Carlo, M. I.; Khan, N.; Zehir, A.; Patil, S.; Ged, Y.; Redzematovic, A.; Coskey, D. T.; Hyman, D. M.; Ladanyi, M.; Chen, Y. B.; more...
    JCO Precision Oncology (2019)

    Fulltext@MSK | Save
  • Results from a randomised phase I/II trial evaluating the safety and antitumour activity of anti-PD-1 (MEDI0680)/anti-PD-L1 (durvalumab) vs anti-PD-1 (nivolumab) alone in metastatic clear cell renal cell carcinoma (ccRCC)
    Meeting Abstract

    Voss, M. H.; Azad, A. A.; Hansen, A. R.; Gray, J. E.; Welsh, S. J.; Achour, I.; Hu, H.; Lewis, L.; Walcott, F. L.; Oosting, S. F.
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Towards individualized therapy for metastatic renal cell carcinoma
    Review

    Kotecha, R. R.; Motzer, R. J.; Voss, M. H.
    Nature Reviews Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Comparative genomic profiling from tumor tissue and circulating tumor DNA (ctDNA) in 111 patients (Pts) with metastatic clear cell renal cell carcinoma
    Meeting Abstract

    Kotecha, R.; Gedvilaite, E.; Murray, S. J.; Motzer, R. J.; Tsui, D.; Voss, M. H.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Association of body mass index (BMI) with clinical outcomes in 203 metastatic clear cell renal cell carcinoma (ccRCC) patients (pts) treated with immuno-oncology (IO) agents
    Meeting Abstract

    Ged, Y.; Lee, C. H.; Sanchez, A.; Duzgol, C.; Chaim, J.; Carlo, M. I.; Foster, A.; Akin, O.; Feldman, D. R.; Hakimi, A. A.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Systemic therapy for advanced clear cell renal cell carcinoma (ccRCC) after progression on immune-oncology plus VEGF targeted therapy combinations (IO-VEGF)
    Meeting Abstract

    Ged, Y.; Gupta, R.; Duzgol, C.; Shapnik, N.; Redzematovic, A.; Kotecha, R.; Voss, M. H.; Feldman, D. R.; Akin, O.; Patil, S.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Outcomes of patients with metastatic clear cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors
    Meeting Abstract

    Shah, A. Y.; Kotecha, R.; Lemke, E.; Chandramohan, A.; Chaim, J.; Msaouel, P.; Xiao, L.; Gao, J.; Campbell, M. T.; Zurita, A. J.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • CB-839, a glutaminase inhibitor, in combination with cabozantinib in patients with clear cell and papillary metastatic renal cell cancer (mRCC): Results of a phase I study
    Meeting Abstract

    Meric-Bernstam, F.; Lee, R. J.; Carthon, B. C.; Iliopoulos, O.; Mier, J. W.; Patel, M. R.; Tannir, N. M.; Owonikoko, T. K.; Haas, N. B.; Voss, M. H.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Genomic biomarkers of response to nivolumab/ipilimumab (nivo/ipi) and nivolumab (nivo) monotherapy in 108 patients with advanced renal cell carcinoma
    Meeting Abstract

    Lee, C. H.; Di Natale, R. G.; Chowell, D.; Makarov, V.; Redzematovic, A.; Murray, S. J.; Carlo, M. I.; Voss, M. H.; Feldman, D. R.; Motzer, R. J.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save